Key Acquisition for Naked Brand Group Inc (NASDAQ:NAKD)

Naked Brand Group Inc (NASDAQ:NAKD)

Naked Brand Group Inc (NASDAQ:NAKD) shares are up over 30% before lunch on news that it has acquired the sole owner of intimate clothing brand Frederick’s of Hollywood global online license. NAKD shares end Tuesday at $1.26 but before lunch shares had hit $1.82 on a volume figure over 18 times the daily average.

Naked Brand Group Inc (NASDAQ:NAKD)
One month daily candle-bar graph for $NAKD

Naked, Bendon, and Bendon Group Holdings Limited (“Holdco”) recently entered into a merger agreement under which both of Naked and Bendon will become wholly owned subsidiaries of Holdco, a newly formed Australian holding company.

Bendon will acquire all of the outstanding common stock of FOH in exchange for the forgiveness of debt owed by FOH to Bendon. As a result, Bendon will control FOH’s existing license to develop and sell online products under the Fredrick’s of Hollywood name. As part of the transaction, Holdco will issue to FOH shares, which would have otherwise been issued to Bendon at the time of the merger. Most of these shares will be transferred to the affiliate of Bendon which initially funded FOH. The issuance of the Holdco shares is expected to have a minimal impact on the amount of shares Naked Brand Group Inc (NASDAQ:NAKD) stockholders will have in Holdco.

Naked Brand Group Inc (NASDAQ:NAKD) sales have increased each year since 2015 when the company reported $0.6 million in sales. That number was followed by annual sales figures of $1.4 million and $1.8 million. However profit has been harder to grasp for the apparel company. In 2015, Naked Brand Group Inc (NASDAQ:NAKD) shareholders suffered a per share loss of (-$23.33). That loss narrowed in 2016 to (-$10.13), then narrowed again in 2017 to (-$1.77).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NAKD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) Debuts on TSX After German Expansion

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF)

Shares of AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) jumped 5.31% after the company made its debut on the Toronto Stock Exchange. Trading on Canada’s flagship stock exchange marks yet another milestone achievement for a company that has added more than $600 million in shareholder value and seen its monthly revenues more than triple over the past year.

Aurora Cannabis $ACBFF
Two Month Chart for $ACBFF

Toronto Stock Exchange Milestone

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) shares are currently trading on the flagship exchange under the symbol ACB. Its shares have also been voluntarily delisted from the TSX Venture Exchange. The upgrade, according to the Chief Executive Officer Terry Booth, reflects the remarkable commercial and operational progress made since late last year.

“We are achieving record yields at our Mountain View County production facility, progressing rapidly with the construction of our 100,000+ kg per annum Aurora Sky facility at Edmonton International Airport, and are executing consistently on our national and international expansion strategy,” said Mr. Booth.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) is a licensed producer of medical cannabis with operations in the U.S. and Canada. The company currently operates a 55,200 square foot, state of the art facility from where it develops its proprietary cannabis products. It is also in the process of constructing a second 800,000 square foot production facility as it looks to strengthen its position in the fast growing industry.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) is currently in the process of acquiring its third production facility in Pointe Claire, Quebec, to further support domestic growth. In addition to pursuing growth opportunities back at home, Aurora Cannabis is also looking to grow its footprint on the international scene.

Germany Expansion

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF), through its subsidiary Pedanios, has passed the first application to become a licensed medical cannabis operator in Germany. The subsidiary is set to participate in a second and final stage of the application process. The process involves contract negotiations for cultivation, processing, storing, packaging and delivery of medical cannabis products.

Pedanios is German’s largest importer, exporter, and distributor of medical cannabis. The company has shipped to more than 1,000 German pharmacies. Germany is poised to be one of the biggest markets in medical cannabis given that the country’s healthcare system covers the cost of medical cannabis. A population of more than 80 million people also presents a unique target market that AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) can rely on for sales growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACBFF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

DryShips Inc. (NASDAQ:DRYS) Shares Crumble On Stock Manipulation Claims

DryShips Inc. (NASDAQ:DRYS)

Shares of DryShips Inc. (NASDAQ:DRYS) crumbled in Friday’s trading session after the company became the subject of class action lawsuits over claims of stock manipulation. The stock was down by 27.91% to end the week at $2.17 a share. Last week’s sell off also came after the company effecting another reverse stock split and issuing an updated financial report.

Stock Manipulation Claims

DryShips Inc. (NASDAQ:DRYS) is an international shipping company that operates ocean cargo vessels worldwide. The firm operates through two segments – drybulk and offshore support. Founded in 2014, the company currently owns 13 Panamax Drybulk vessels, and 6 offshore support vessels.

The Greek carrier finds itself in a tight spot over stock manipulation claims that have seen it shed more than 90% in value over the last six months. Law firms behind the class action lawsuits allege that in a series of transactions beginning last year, DryShips Inc. (NASDAQ:DRYS) raised hundreds of millions of dollars by selling newly issued shares directly to Kalani Investments Ltd.

The money that came from Kalani allowed the shipping company to double the size of its fleet even as the stock continued to plunge.

Reports indicate that the company sold the vast numbers of newly issued shares to the British Virgin Island firm at a discount. The firm in return unloaded most of the shares immediately after the stock soared to all-time highs in November, followed by the stock’s plunge.

In their class action lawsuits, law firms allege that because Kalani purchased the shares with the intention of reselling them immediately the transactions amounted to ‘Pseudo underwriting.’

Reverse Stock Split

In a bid to counter the downward pressure, DryShips Inc. (NASDAQ:DRYS) has resorted to reverse stock splits as it tries to stay afloat. Late last year, the company carried out a 1:15 reverse stock split as it sought to strengthen the value of its share price. The company is also fresh from effecting a 1:7 reverse stock split as it tries to shore up the share price even further.

Extreme dilution is now a point of concern given the amount of DryShips Inc. (NASDAQ:DRYS) shares that are floating in the market. A massive net loss in the recent quarter has also rattled investors fuelling the sell-off wave that now threatens to push the stock to all-time lows. The company has already suspended debt payments arousing concerns over its financial stability.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRYS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Moleculin Biotech Inc (NASDAQ:MBRX) Spikes On MD Anderson Cooper Center Technology Licensing Agreement

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) traded higher in Tuesday’s trading session after announcing the signing of a new technology license agreement with MD Anderson Copper Center for the Leukemia drug Annamycin. The stock was up by 20.59% to end the day at $2.05 a share. The rally also comes after the company regained compliance with the NASDAQ Listing Requirements.

Moleculin Biotech Inc (NASDAQ:MBRX)
Bar Graph $MBRX

Technology License Agreement

Moleculin Biotech Inc (NASDAQ:MBRX) is a preclinical stage pharmaceutical company specializing in the development of anti-cancer drugs. Annamycin is the company’s lead drug candidate for the treatment of refractory acute myeloid leukemia. The company is also working on two other molecular portfolios, one of which is working on the modulation of hard-to-target tumor cell signaling mechanisms. The other molecule targets the metabolism of tumors.

The technology license agreement with MD Anderson’s Cooper Cancer Center is based on new patent applications that Moleculin is set to file. The patents are in relation to the company’s candidate drug Annamycin.

“In anticipation of beginning our planned clinical trials for Annamycin. One of our priorities has been to ensure the best possible protection for our intellectual property. Some key patent applications had yet to be filed and signing a new license agreement with MD Anderson clears the way for those patents,” said Walter Klemp, Moleculin Biotech Inc (NASDAQ:MBRX) CEO.

Dr. Gill Appointment

Moleculin Biotech Inc (NASDAQ:MBRX) has already appointed Dr. Lidia Gil of Poznan University to act as the lead European Principal Investigator. Dr. Gil is to oversee the planned Phase I/II clinical trial for Annamycin for the treatment of acute myeloid leukemia. The company has also expanded its engagement with CRO to include clinical sites in Poland.

Mayo Clinic WP1066 Partnership

Separately, Moleculin Biotech Inc (NASDAQ:MBRX) has entered into an agreement with Physicians at the Mayo Clinic as part of an effort that seeks to enable additional research on WP1066 molecule as a possible treatment for a rare form of pediatric tumors.

Under the terms of the agreement, the company is to supply Mayo Clinic physicians and scientists with WP1066 for preclinical testing as a novel treatment for Pediatric Diffuse Intrinsic Pontine Gliomas. The primary target with the upcoming trials is cell signaling protein STAT3. Initial studies have shown that WP1066 has the potential to suppress xenograft of human brain tumors transplanted into mice

“This, along with the physician efforts at MD Anderson to secure an IND to study WP1066 for the treatment of adult brain tumors, continues to validate the potential importance of WP1066 in the treatment of difficult tumors,” said Mr. Klemp.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Is RightsCorp Inc (OTCMKTS:RIHT) on the Rocket Pad?

RightsCorp Inc (OTCMKTS:RIHT)

RightsCorp Inc (OTCMKTS:RIHT) has been posting news that observers believe may propel shares higher in the coming weeks. Currently, RIHT shares are trading well above their 52-week low of $0.01 per share and are within striking distance of their $0.059 52-week high.

RightsCorp Inc (OTCMKTS:RIHT)
Daily Candle Bar for $RIHT

Intellectual property (IP) protection is a huge business. The U.S. Chamber of Commerce Intellectual Property Center has calculated the worth of intellectual property in the United States as being between $5 trillion and $5.5 trillion. Reports suggest that the U.S. economy loses $58 billion each year to copyright infringement including $16 billion in lost revenue to the owners of the IP, and $3 billion in lost tax revenue.

RightsCorp Inc (OTCMKTS:RIHT) provides data and analytics services to owners of copyrighted property such as artists or media firms. The company’s patent-pending digital technology focuses on the infringement of intellectual property rights and ensures that the legal owner’s rights are protected.

RightsCorp Recent History

At the end of February, RightsCorp Inc (OTCMKTS:RIHT) announced Mr. Cecil Bond Kyte as the company’s new Chief Executive Officer. Mr. Christopher Sabec, the Company’s current CEO, will serve as President and continue to spearhead RightsCorp’s intellectual property litigation support and copyright monetization services.

In late June, RightsCorp Inc (OTCMKTS:RIHT) announced that it has been granted an Israeli Patent for the company’s “System to Identify Multiple Copyright Infringements and Collecting Royalties”. Cecil Bond Kyte, CEO of Rightscorp, stated “Online piracy continues to be a major concern worldwide with Israel holding one of the highest rates outside Europe. Last year, it was recorded that approximately 66% watch movies and TV shows online with only 2% using legal direct-view websites. There is a need in Israel for content protection and our technology is an ideal solution for curbing piracy,”.

RightsCorp Can Scale

Clearly, there is positive movement in the ability for RightsCorp to execute on their business model. Their approach is to use their proprietary software to monitor global Peer‐to‐Peer (P2P) file sharing networks. As they monitor the P2P network, the software continuously scans for illegally downloaded digital media.

Once the software finds an illegally downloaded file, it sends an email to the internet service provider (ISP) using the notice format as specified in the Digital Millennium Copyright Act. The notice includes the date, time, song title and other specific technology identifiers to confirm the infringement by the ISP’s customer. Under Federal Copyright Law, once the ISP has actual knowledge of copyright infringements that take place using its network, it has specific duties in relation to the enforcement of the rights of the owners of the material in question. The ISP can legally cut off service to repeat offenders.

Fines for downloading IP without proper authority or permission can reach $150,000 per violation. However, RightsCorp provides these illegal users with a link to remit payment to Rightscorp who will then pay the IP owner a percentage of the collected fee. RightsCorp Inc (OTCMKTS:RIHT) believes this arrangement is economical and mutually beneficial to both the infringer and owner of the IP.

One thing is certain if the company is able to fully execute its business model – it could be a massive cash-flow generating machine.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RIHT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant

VOXX International Corp (NASDAQ:VOXX)’s Q1 2018 Sales Growth Offsets Net Loss Concerns

VOXX International Corp (NASDAQ:VOXX)

VOXX International Corp (NASDAQ:VOXX) traded higher in Monday trading session after posting modest top line growth in Q1 2018. A 17.4% increase in Premium Audio sales helped offset investors’ concerns about a (-$3) million loss in the quarter.

$VOXX Daily Candle graph
Candle Graph $VOXX

VOXX International Corp (NASDAQ:VOXX) is a renowned worldwide leader in automotive consumer electronics. The company boasts of an extensive distribution network that includes power retailers, mass merchandisers and 12-volt specialists. Its footprint extends into some of the biggest markets in Europe, Asia, Mexico, and South America.

VOXX Q1 2018 Financial Results

Net sales for the quarter ending May 31, 2017, increased by 3.6% to $159.1 million compared to $155.5 million reported a year ago. Gross margin, however, dropped to 27.5% from 29.7% due to increased promotion activities geared towards clearing inventory levels.

VOXX International Corp (NASDAQ:VOXX) expects gross margins to improve in the second quarter due to new products coming to market and partnerships in the Automotive and Consumer Accessories segments.

Operating expenses dropped to $51.6 million from $53.2 million as of Q1 2017. Net loss attributed to shareholders dropped to ($3) million from (-$4.3) million reported in Q1 2017. Operating net loss, on the other hand, increased to $7.8 million from $7.1 million as of last year.

Hirschmann Car Communication GmbH Sell

During the quarter, the company entered into a definitive agreement with a subsidiary of TE Connectivity Ltd for the sale of Hirschmann Car Communication GmbH and its subsidiaries. The chief Executive Officer, Pat Lavelle, expects the transaction to lead to a greater concentration of the company’s business in North America.

“While Hirschmann has been a great contributor to our business and has the industry-leading technology, we believe the opportunity to sell at the proposed value is a benefit for our shareholders. Upon completion, we will have a clean balance sheet, lower working capital needs and we expect greater cash flow,” said Mr. Lavelle.

Under the terms of the agreement, Voxx International is to receive €148.5 million for the unit. The transaction is subject to regulatory approval among other customary closing conditions.

VOXX International Corp (NASDAQ:VOXX) Shares have been on an impressive run since the start of the year, a trend that could continue especially with the filling of stellar Q1 2018 financial results. The stock is up by more than 80% since the start of the year having tripled in value in the last 12 months.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VOXX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

FDA Concerns Over Ocular Therapeutix Inc. (NASDAQ:OCUL) Manufacturing Process

Ocular Therapeutix Inc. (NASDAQ:OCUL)

Shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) plunged 25.05% in Friday’s trading session as investors reacted to concerns raised by the U.S. Food and Drug Administration (FDA) about the company’s manufacturing processes. The resignation of the entire management team also continues to fuel a selloff of the stock – a problem that has since attracted a wave of class action lawsuits.

The biopharmaceutical company bills itself as a leading developer of innovative therapies, using the hydrogel platform technology, for diseases and conditions affecting the eye. The company’s lead candidate product DEXTENZA has already completed its Phase 3 clinical trial as a novel treatment for ocular pain after ophthalmic surgery.

Ocular Therapeutix Inc. (NASDAQ:OCUL) has filed an NDA resubmission for DEXTENZA awaiting the final FDA stance on the product. The company is also evaluating a number of injectable drug delivery depots for back-of-the-eye diseases.

Manufacturing Concerns

Ocular Therapeutix Inc. (NASDAQ:OCUL) appears to be facing serious manufacturing issues after the Food and Drug’s Administration raised concerns in a second 483 statement. The agency, after carrying out an inspection of the company’s manufacturing plant, says it discovered an unknown matter in the company’s candidate product DEXTENZA.

The FDA has since accused the biopharmaceutical company of releasing the product without carrying out a risk assessment on its quality or safety. In one of the observations, the FDA raises concerns about the company’s laboratory controls which it says does not include scientifically sound and appropriate test procedures that can guarantee high-quality products.

The company has also been taken to task for not providing written procedures for production and process controls that can affirm products and drugs have the strength and quality they purport to have.

Management Stance

Many observers believe the management has yet to grasp the magnitude of the matter if remarks by the chief executive officer, Amar Shawnee, during Q1 earnings call is anything to go by.

“We were pleased during the re-inspection that the FDA investigator was able to confirm our corrective action plan from prior observations, and indicated that there was no further follow-up necessary to close out those issues. So I think that’s a strong sign that the manufacturing process has moved forward significantly, and is in a fully developed mode,” said Mr. Shawnee.

Ocular Therapeutix Inc. (NASDAQ:OCUL) maintains that its manufacturing process is fully developed and that the concerns raised can be resolved quickly. However, the company needs to revamp the manufacturing process if its lead product DEXTENZA is to stand a chance of gaining the much needed FDA approval.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OCUL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms

Cerulean Pharma Inc (NASDAQ:CERU) Explodes On Dare Bioscience Merger Push

Cerulean Pharma Inc (NASDAQ:CERU)

Shares of Cerulean Pharma Inc (NASDAQ:CERU) more than doubled in market value after Dare Bioscience Chief Executive Officer Sabrina Martucci Johnson requested that shareholders approve a proposed merger. The stock was up by 143.69% in Wednesday’s trading session to end the day at $1.13 a share.

Cerulean Pharma Inc (NASDAQ:CERU) has also sought to accelerate the merger push by asking its shareholders to approve a sale of its dynamics Tumor Targeting Platform technology pursuant to a Novartis Asset Purchase Agreement. The company also wants shareholders to approve a reverse stock split at a ratio ranging from 10:1 to 20:1.

Cerulean Pharma Inc (NASDAQ:CERU) is a clinical stage company that specializes in the development of therapies in areas of oncology and other diseases. The company is currently working with Novartis Institute for Biomedical Research to develop nanoparticle-drug conjugates. Dare Bioscience bills itself as a healthcare company focused on developing and commercializing products for women’s reproductive health. Ovaprene, a novel non-hormonal contraceptive, will become the combined company’s lead candidate drug. The drug seeks to address an unmet need in the $19 billion a year contraception market.

Merger Agreement

On March 19, 2017, Cerulean Pharma Inc (NASDAQ:CERU) entered into a definitive agreement for the purchase Dare Biosciences issued and outstanding capital stock. The fate of the proposed merger rests in the hands of shareholders who are set to vote on the management proposal at the upcoming special meeting on July 19, 2017.

“As the founder and CEO of Dare Bioscience, Inc. (“Dare”), I am excited by the prospect of Dare combining with Cerulean Pharma Inc. (“Cerulean”). [..]. We believe a segment of this market is underserved, which gives us an opportunity to create value for stockholders,” said Mr. Johnson.

Cerulean Pharma Inc (NASDAQ:CERU) shareholders will own between 30% and 49% of the combined company upon the deal closing. The combined company will operate under the name Dare Bioscience Inc. under the leadership of Mr. Johnson as the CEO and Lisa Walters-Hoffert as the Chief Financial Officer. The board of directors will consist of William H. Rastetter, Susan L. Kelley, Roger L. Hawley, Robin J. Steele and Sabrina Martucci Johnson

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERU and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Update on Celsion Corporation (NASDAQ:CLSN) Sends Shares Booming!

Celsion Corporation (NASDAQ:CLSN)

Shares of Lawrenceville, NJ-based Celsion Corporation (NASDAQ:CLSN) are up over 36% in the first hour of trading. Volumes are extraordinarily heavy. CLSN shares closed Monday at $2.02 and gapped up to open this morning at $2.63 on the biotech company’s update regarding its Phase 1b dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.

NASDAQ:CLSN
Daily candle bar graph

Founded in 1982, Celsion Corporation develops and directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. Celsion Corporation (NASDAQ:CLSN)’s lead product candidate, ThermoDox, is in Phase 3 clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. Celsion Corporation (NASDAQ:CLSN) is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers.

According to Celsion Corporation (NASDAQ:CLSN)’s press release:

  • Of the fourteen patients treated to date, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate (DCR) and an 86% objective response rate (ORR).
  • Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses.
  • Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.
  • Of the five patients treated at the highest dose cohort, all five patients (100%) experienced a R0 surgical resection.
  • Of the seven patients who have received GEN-1 treatment over one year ago and are being followed, only one patient’s cancer has progressed after 11.7 months.

Celsion Corporation (NASDAQ:CLSN) is followed by three investment firms. Two analysts rate CLSN shares as a “Strong Buy” and one rates the shares as a “Hold”. Their consensus price target is over $15. CLSN shareholders have had their shares diluted every single year since 2012 when there were 550,000 shares outstanding. By 2016 that number had ballooned to 1.85 million. EPS losses have also been standard since 2012 when the company posted a loss of (-$48.11) per shares. In 2016 that loss shrank to (-$11.90).

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. All information, or data, is provided with no guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Freedom Leaf Inc (OTCMKTS:FRLF) Acquires Green Market Europe

Freedom Leaf Inc (OTCMKTS:FRLF)

Freedom Leaf Inc (OTCMKTS:FRLF), which focuses on marijuana industry mergers and acquisitions, has signed an intent letter of acquisition with Green Market Europe owners. The acquisition will see Freedom Leaf take ownership of an operational greenhouse that measures more than 60,000 square feet. Shares of Freedom Leaf fell by 1.94% to $0.0505 on Thursday.

The greenhouse consists of more than 20,000 square feet equipped with a light deprivation system necessary for the stimulation of flowering throughout the year. An additional 200 acres are also available for outdoor production and thus the capacity for both outdoor and greenhouse production can be scaled up if necessary.

No debt

All the facilities that will be acquired from Green Market Europe are free of debt. The acquisition will include all assets belonging to Green Market Europe such as purchase orders that are more than $450,000, production agreements with local farmers, intellectual property, greenhouse equipment, leasehold improvements, and land leases.

The chief executive officer and co-founder of Freedom Leaf Inc (OTCMKTS:FRLF), Clifford Perry, said the acquisition would turn the company into a major player in the industry.

“With this transformative acquisition Freedom Leaf has become a major participant not only in the booming CBD (cannabidiol) industry, but in many other aspects of the global hemp industry,” said Perry.

Some of the development projects that Freedom Leaf Inc (OTCMKTS:FRLF) is engaged in includes rare cannabinoids research. Hemp seed oil, making furniture and footwear from fabric derived from hemp, phytocannabinoid oil, and CBD drinks.

Spanish Mediterranean coast

Miguel Hernandez University, an institution which possesses extensive facilities for research and development, is collaborating with Green Market Europe in fertilizer testing projects, LED growing systems, and genetic breeding.

Operations are in the Callosa de Segura area of Alicante, Spain and close to Elche city on the southeastern Mediterranean coast. Due to the favorable and moderate climate, multiple crops can be produced every year.

Natural Hemp was started in 2013 by Vicente Javaloyes Martinez and Luis Miguel Santos is the predecessor of Green Market Europe.

One of the agreements contained in the intent letter is that the current management of Green Market Europe will be retained. The acquisition will consist of a common stock transaction of 4,800,000 shares belonging to Freedom Leaf as well as 20,000 euros in cash. Shareholders of Green Market Europe will get to keep half of the profits that have been generated. The flagship publication of Freedom Leaf Inc (OTCMKTS:FRLF) is Freedom Leaf Magazine.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FRLF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.